Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jason Timothy Henry"'
Autor:
Emma G. Sturgill, Sahiti Kolli, Kavanya Feustel, Daniel Luckett, Carissa Jones, Marilyn Elaine Holt, Annastasia Hyde, Suzanne Fields Jones, Cesar Augusto Perez, Judy S. Wang, Stephen G. Divers, Meredith Pelster, Jason Timothy Henry, David R. Spigel, Howard A. Burris III, Andrew Jacob McKenzie
Publikováno v:
Journal of Clinical Oncology. 41:738-738
738 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with an overall 5-year survival rate of ~10%. Therapies targeting KRAS G12D, a prevalent molecular driver of PDAC, represent an active area of investigation with
Autor:
Cesar Augusto Perez, Jason Timothy Henry, Andreas Varkaris, Vivek Subbiah, Alexander I. Spira, Oleg Schmidt, Jinshan Shen, Wei Guo, Tamieka Hunter, Kai Yu Jen, Mahesh Padval, Djuro Karanovic, Beni B. Wolf, Erika P. Hamilton
Publikováno v:
Journal of Clinical Oncology. 40:TPS1124-TPS1124
TPS1124 Background: Targeting constitutively active mutant kinases with selective small molecule inhibitors is a key therapeutic pillar of precision oncology. Phosphatidylinositol-4,5bisphosphate-3 kinase, catalytic subunit alpha ( PIK3CA) mutations
Autor:
Jennifer Robinson Diamond, Jason Timothy Henry, Gerald Steven Falchook, Anthony J. Olszanski, Harshabad Singh, E. Jane Leonard, Richard C. Gregory, Vicky A. Appleman, John Gibbs, Carole Harbison, Cong Li, Jessica M. Sapiro, Tomoki Yoneyama, Alexander A Parent, Vincent Chung
Publikováno v:
Journal of Clinical Oncology. 40:TPS2690-TPS2690
TPS2690 Background: Tumor resistance to immune checkpoint inhibitors (CPIs), including pembrolizumab, is common. Suggested mechanisms of resistance include reduced interferon (IFN) signaling, immune escape, and immunosuppressive tumor phenotypes. Inn